此外，相关临床试验数据显示，P9菌株可促进体内农药残留的排出，减轻农药暴露引起的炎症反应。 产品另一核心菌株植物乳植杆菌CN2018源自江南大学研究，该菌株具有耐酸性，试验显示其对幽门螺 杆菌生长有抑制作用。这两项研究成果都已获得国家专利，而多项尖端科研成果与专利的加持，也为这 份年礼增添了一份沉甸甸的科学"含金量"。 除了顶级的科研与学术背书，江中P9益生菌还拥有深厚的"航天基因"。此前，江中P9益生菌正式获中 国航天基金会授予"中国航天事业合作伙伴"荣誉，这不仅是对其科研实力的认可，更是对其航天级严苛 品质的肯定。春节送礼，这样一份拥有太空科研背景且具备航天级品质保障的礼物，更能体现出送礼者 诚挚的心意。 随着春节的临近，挑选一份既有心意又显体面的年礼成为许多人的考量。近年来，大众的健康意识显著 提升，送礼的逻辑也从传统的"烟酒糖茶"转向了更健康更实用的健康产品。江中制药旗下的P9益生菌冻 干粉，凭借深厚的品牌积淀、硬核的科研成果与扎实的产品实力，成为今年春节年礼的代表作，以中国 航天事业合作伙伴的身份，拥有非同寻常的"航天级品质"与健康分量。 在益生菌行业，一直有"中国菌更适合中国肠胃"的共识。国人的饮 ...

Core Viewpoint - The company is expanding its business in the internet healthcare and health products sector by establishing a new company in partnership with Hubei Hejun Tenghui Trading Co., Ltd. [1] Group 1: Investment Details - The new company will be established with a registered capital of 3 million yuan, with the company contributing 1.8 million yuan for a 60% stake and Hubei Hejun Tenghui Trading Co., Ltd. contributing 1.2 million yuan for a 40% stake [1] - The registered address of the new company will be in Wuhan, Hubei Province, and its business scope includes internet information services for medical devices and online sales of food [1] Group 2: Strategic Implications - The investment aims to enhance the company's market competitiveness and expand its business layout in the internet healthcare and health products sectors [1] - The transaction does not constitute a related party transaction or a major asset restructuring, and it does not require approval from the company's shareholders [1] - The company anticipates that this investment will not have a significant impact on its financial status for the current year but will positively influence its ongoing operational capacity and overall competitiveness in the future [1]

Core Insights - PepsiCo reported third-quarter earnings that exceeded Wall Street expectations, with revenue of $23.94 billion and adjusted earnings per share of $2.29, surpassing forecasts of $23.85 billion and $2.27 respectively [1] - The North American beverage segment showed a 2% growth, marking the highest growth rate in nearly two years, which offset the ongoing slowdown in the food business [1] - The acquisition of the health soda brand Poppi contributed significantly to growth, with retail sales increasing over 50% year-over-year [1] Financial Performance - Total revenue for the quarter reached $23.94 billion, slightly above the expected $23.85 billion [1] - Adjusted earnings per share were reported at $2.29, exceeding the market expectation of $2.27 [1] - The North American beverage business achieved a 2% growth, counterbalancing a 3% decline in food sales [1][2] Regional Performance - The EMEA region experienced a revenue growth of 5.5%, while Latin America saw a 4% increase, helping to mitigate the weakness in North American food sales [2] - The company anticipates low single-digit organic revenue growth for 2025, with core constant currency earnings expected to remain flat compared to the previous year [2] Management Changes - PepsiCo announced a management change, with CFO Jamie Caulfield set to retire and Steve Schmitt appointed as the new CFO effective November 10 [2] - Darren Walker will also retire from the board, with the change effective November 19 [2] Strategic Focus - The company is expanding its portfolio to include healthier, high-protein, and portion-controlled products in response to changing consumer preferences [2] - PepsiCo is facing pressures from economic uncertainties and health policy impacts [2] Investor Pressure - Elliott Investment Management holds approximately $4 billion in PepsiCo shares and is urging the company to evaluate and streamline its snack product portfolio [3]